0.40Open0.40Pre Close0 Volume388 Open Interest300.00Strike Price0.00Turnover78.57%IV27.32%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier9DDays to Expiry0.40Extrinsic Value100Contract SizeAmericanOptions Type0.0351Delta0.0026Gamma589.88Leverage Ratio-0.1137Theta0.0021Rho20.71Eff Leverage0.0297Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet